Literature DB >> 18058925

Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus.

Matthew N Hill1, Erica J Carrier, W-S Vanessa Ho, Leyu Shi, Sachin Patel, Boris B Gorzalka, Cecilia J Hillard.   

Abstract

Experimental studies indicate a bidirectional, functional relationship between glucocorticoids and the endocannabinoid system; however, the effects of repeated glucocorticoid treatment on the endocannabinoid system have not been examined. In this study, we treated male rats with either a single dose or a 21-day course of treatment with corticosterone (20 mg/kg) and measured hippocampal cannabinoid CB(1) receptor expression and endocannabinoid content. The 21-day, but not the single, administration of corticosterone significantly reduced both the binding site density and amount of protein of the hippocampal cannabinoid CB(1) receptor without affecting affinity for the CB(1) receptor agonist, [(3)H]CP55940. With regard to hippocampal endocannabinoid content, acute corticosterone treatment resulted in a significant reduction in anandamide but did not affect 2-arachidonylglycerol, while repeated corticosterone treatment did not alter content of either anandamide or 2-arachidonylglycerol. These data support the hypothesis that the cannabinoid CB(1) receptor is under negative regulation by glucocorticoids in the hippocampus, and suggest that hippocampal cannabinoid CB(1) receptor signaling could be reduced under conditions associated with hypersecretion of glucocorticoids, such as chronic stress. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18058925     DOI: 10.1002/hipo.20386

Source DB:  PubMed          Journal:  Hippocampus        ISSN: 1050-9631            Impact factor:   3.899


  38 in total

1.  Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice.

Authors:  N P Bowles; M N Hill; S M Bhagat; I N Karatsoreos; C J Hillard; B S McEwen
Journal:  Neuroscience       Date:  2011-09-10       Impact factor: 3.590

2.  Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague-Dawley rats.

Authors:  R J Newsom; C Osterlund; C V Masini; H E Day; R L Spencer; S Campeau
Journal:  Neuroscience       Date:  2011-11-28       Impact factor: 3.590

3.  Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus.

Authors:  Jaclyn I Wamsteeker; J Brent Kuzmiski; Jaideep S Bains
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

4.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

5.  Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B.

Authors:  Pankaj Pandey; Narayan D Chaurasiya; Babu L Tekwani; Robert J Doerksen
Journal:  Biochem Pharmacol       Date:  2018-06-26       Impact factor: 5.858

6.  Endocannabinoids gate state-dependent plasticity of synaptic inhibition in feeding circuits.

Authors:  Karen M Crosby; Wataru Inoue; Quentin J Pittman; Jaideep S Bains
Journal:  Neuron       Date:  2011-08-11       Impact factor: 17.173

7.  Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous system.

Authors:  Shuangsong Hong; Gen Zheng; John W Wiley
Journal:  Gastroenterology       Date:  2014-09-28       Impact factor: 22.682

Review 8.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

Review 9.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

Review 10.  The endocannabinoid system in obesity and type 2 diabetes.

Authors:  V Di Marzo
Journal:  Diabetologia       Date:  2008-06-18       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.